Omada Health (OMDA)
Market Price (5/11/2026): $15.0 | Market Cap: $883.8 MilSector: Health Care | Industry: Health Care Technology
Omada Health (OMDA)
Market Price (5/11/2026): $15.0Market Cap: $883.8 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 49% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -116% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2.9% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 39x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% Key risksOMDA key risks include [1] a significant revenue concentration with a few key customers and [2] ongoing operating and net losses. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 49% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -80%, 3Y Excs Rtn is -116% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2.9% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 39x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% |
| Key risksOMDA key risks include [1] a significant revenue concentration with a few key customers and [2] ongoing operating and net losses. |
Qualitative Assessment
AI Analysis | Feedback
1. Consistent Financial Performance and Upgraded Outlook.
Omada Health demonstrated strong financial performance, beating analyst estimates for both the fourth quarter of 2025 and the first quarter of 2026. In Q4 2025, the company reported earnings per share (EPS) of $0.13, surpassing estimates of -$0.05 by $0.18, and revenue of $75.85 million, exceeding estimates by $4.78 million. The company also achieved its first GAAP net income quarter with $5 million in Q4 2025 and positive full-year adjusted EBITDA of $6 million. This positive momentum continued into Q1 2026, with Omada reporting EPS of -$0.05, beating the consensus estimate of -$0.08 by $0.03, and revenue of $78 million, a 42% increase year-over-year. Notably, Q1 2026 marked a positive adjusted EBITDA of $1 million, a $5 million improvement from Q1 2025. Following these results, Omada raised its full-year 2026 revenue guidance to $322 million-$330 million and adjusted EBITDA guidance to $14 million-$20 million. This consistent overperformance and optimistic financial outlook provided a strong underlying support for the stock, preventing significant declines.
2. Strategic Expansion in the GLP-1 Market and PBM Partnerships.
Omada Health significantly expanded its strategic positioning in the rapidly growing GLP-1 medication market during this period. The company announced new partnerships, notably joining Optum Rx's Weight Engage portfolio and Eli Lilly's Employer Connect program in Q1 2026. These collaborations establish relationships with all three leading Pharmacy Benefit Managers (PBMs), which collectively process 80% of prescription claims and serve most commercially insured lives. Through these direct-to-employer and PBM channels, Omada will offer its GLP-1 Care Track, including clinical evaluation, prescribing, and medication management. While these partnerships promise substantial long-term growth and increased market penetration, the material revenue contributions from some of these newer relationships are primarily anticipated in 2027 rather than 2026. This forward-looking revenue realization likely tempered immediate significant upward stock movement, contributing to a stable trading pattern as investors await the full impact of these strategic initiatives.
Show more
Stock Movement Drivers
Fundamental Drivers
The -0.9% change in OMDA stock from 1/31/2026 to 5/10/2026 was primarily driven by a -33.3% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.95 | 14.82 | -0.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 154 | 283 | 83.5% |
| P/S Multiple | 4.6 | 3.1 | -33.3% |
| Shares Outstanding (Mil) | 48 | 59 | -19.0% |
| Cumulative Contribution | -0.9% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| OMDA | -0.9% | |
| Market (SPY) | 3.6% | 35.4% |
| Sector (XLV) | -6.9% | 21.0% |
Fundamental Drivers
The -39.7% change in OMDA stock from 10/31/2025 to 5/10/2026 was primarily driven by a -62.7% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.57 | 14.82 | -39.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 142 | 283 | 99.8% |
| P/S Multiple | 8.3 | 3.1 | -62.7% |
| Shares Outstanding (Mil) | 48 | 59 | -19.0% |
| Cumulative Contribution | -39.7% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| OMDA | -39.7% | |
| Market (SPY) | 5.5% | 29.9% |
| Sector (XLV) | 0.3% | 16.0% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| OMDA | ||
| Market (SPY) | 30.4% | 22.3% |
| Sector (XLV) | 4.0% | 13.4% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| OMDA | ||
| Market (SPY) | 78.7% | 22.3% |
| Sector (XLV) | 13.0% | 13.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OMDA Return | - | - | - | - | -31% | 4% | -29% |
| Peers Return | -51% | -54% | 7% | 2% | -16% | 10% | -77% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| OMDA Win Rate | - | - | - | - | 29% | 60% | |
| Peers Win Rate | 27% | 38% | 50% | 40% | 35% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| OMDA Max Drawdown | - | - | - | - | -37% | -31% | |
| Peers Max Drawdown | -56% | -68% | -29% | -49% | -30% | -34% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, HIMS, GDRX, AMWL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
OMDA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.7% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
OMDA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Omada Health (OMDA)
AI Analysis | Feedback
Noom for chronic diseases.
A virtual Weight Watchers for managing chronic conditions like diabetes and hypertension.
AI Analysis | Feedback
```html- Cardiometabolic Programs: Virtual care programs designed to manage and prevent prediabetes, diabetes, and hypertension.
- Physical Therapy Program: A virtual program addressing musculoskeletal (MSK) conditions.
- GLP-1 Care Tracks: Specialized support integrated into cardiometabolic programs for members using glucagon-like peptide-1 agonists.
- Behavioral Health Support: Integrated behavioral health services offered across all Omada programs to enhance overall well-being.
AI Analysis | Feedback
Omada Health (OMDA) sells its programs primarily to other companies and entities that cover the cost for individuals. Based on the provided description, the company does not name specific customer companies. Instead, it identifies the following categories of organizations as its major customers and channel partners:
- Employers: These entities cover Omada's programs for their employees and their dependents.
- Health Systems: These entities cover Omada's programs for their patients.
- Health Plans: These entities either cover Omada's programs for a portion of their members as direct customers or act as channel partners reselling the programs.
- Pharmacy Benefit Managers ("PBMs"): These entities act as channel partners, reselling Omada's programs to their own end customers, which are typically employers.
AI Analysis | Feedback
nullAI Analysis | Feedback
Sean Duffy, Co-Founder & Chief Executive Officer
Sean Duffy co-founded Omada Health in 2011 with the goal of revolutionizing healthcare for chronic diseases by merging medical trends and technology. Before Omada Health, he created Excel Everest, an interactive Microsoft Excel training tool, and worked as an editor for Medgadget, a medical technology blog. He also held roles at Google and IDEO. Duffy began his journey with a background in medicine and technology, having pursued dual MD/MBA degrees at Harvard.
Steve Cook, Chief Financial Officer
Steve Cook joined Omada Health as Chief Financial Officer in 2021. He brings over a decade of experience in financial strategy, having previously served as Vice President and Head of Strategic Finance at One Medical, where he guided their strategic finance efforts through its 2020 IPO. Prior to that, Cook spent six years in finance and strategy at Salesforce.
Wei-Li Shao, President
Wei-Li Shao joined Omada Health in 2019 and serves as its President. He has over 20 years of global healthcare experience, including executive roles at Eli Lilly and Company, where he built and led biopharmaceutical and diagnostic imaging businesses in various countries, including the United States, China, and New Zealand.
Carolyn Jasik, Chief Medical Officer
Carolyn Jasik serves as the Chief Medical Officer of Omada Health. She brings expertise in clinical care and is instrumental in integrating medical best practices within Omada's virtual care programs.
Sunil Kayiti, Chief Technology Officer
Sunil Kayiti is the Chief Technology Officer at Omada Health. He is responsible for the technology and platform enhancements that support Omada's virtual care programs.
AI Analysis | Feedback
The key risks to Omada Health's business include:
-
History of Net Losses and Path to Profitability: Omada Health has a history of net losses and has not yet achieved profitability on an annual basis, which is attributed to significant investments in program and platform enhancements.
-
Reliance on Customers, Channel Partners, and Evolving Reimbursement Models: Omada Health's revenue is dependent on securing and retaining contracts with employers, health plans, health systems, pharmacy benefit managers ("PBMs"), and other entities that cover the cost of their programs for covered individuals. Changes in the willingness of these customers and channel partners to cover or resell Omada's programs, or shifts in the broader healthcare reimbursement landscape, could significantly impact the company's financial performance.
AI Analysis | Feedback
nullAI Analysis | Feedback
NullAI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Omada Health (OMDA) over the Next 2-3 Years:
- Expansion and Adoption of GLP-1 Related Programs: Omada Health anticipates significant revenue growth from its GLP-1 Care Track, driven by employer demand to maximize the value of their GLP-1 investments. The company has launched new offerings, including GLP-1 prescribing and GLP-1 Flex Care, which provides employers with a structured way to connect eligible employees with clinical evaluation, prescribing, and ongoing medical oversight for GLP-1s alongside Omada's lifestyle and behavioral support. This initiative is expected to cater to the growing market for anti-obesity medications and associated care.
- Growth of the Multi-Condition Care Platform and New Condition Launches: Omada continues to expand the reach and depth of its integrated multi-condition care platform, which already addresses cardiometabolic conditions (prediabetes, diabetes, hypertension), musculoskeletal (MSK) conditions, and behavioral health. The launch of "Omada for Cholesterol" in February 2026 further strengthens its cardiometabolic offerings and expands the scope of its platform, allowing the company to address more prevalent and often comorbid chronic conditions.
- Customer Acquisition and Deeper Penetration within Existing Customer Accounts: Omada Health's revenue growth is also expected from acquiring new customers, which include employers, health plans, health systems, and pharmacy benefit managers (PBMs). Furthermore, the company aims for deeper penetration within its existing customer base, expanding the number of programs and members covered per account. Omada's strong customer satisfaction and high net dollar retention rates (128% in 2024) indicate successful existing relationships that can drive further expansion.
- Leveraging Artificial Intelligence (AI) for Enhanced Engagement and Program Efficacy: Omada is strategically investing in and deploying AI-powered tools, such as OmadaSpark and Meal Map, launched in 2025, to enhance member engagement and optimize care delivery. These AI-supported tools are designed to provide personalized healthcare experiences, offer 24/7 access to resources, and assist human-led care teams, ultimately contributing to better health outcomes and increased member retention, which indirectly supports revenue growth.
AI Analysis | Feedback
Share Issuance
- Omada Health completed its Initial Public Offering (IPO) in June 2025, offering 7.9 million shares at $19.00 per share.
- The IPO successfully raised $150 million for the company.
- The offering included a 30-day option for underwriters to purchase up to an additional 1.185 million shares.
Inbound Investments
- Prior to its IPO, Omada Health had raised over $500 million in total funding.
- In February 2022, the company secured $192 million through a Series E funding round, which led to its valuation as a unicorn.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Omada Health Stock Pre-Market (+10%): Q4 Beat, Surprise Profit & Strong 2026 Guidance | 03/06/2026 | |
| Omada Health Earnings Notes | 12/16/2025 | |
| Is Omada Health Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OMDA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.97 |
| Mkt Cap | 0.9 |
| Rev LTM | 788 |
| Op Inc LTM | -8 |
| FCF LTM | 57 |
| FCF 3Y Avg | 94 |
| CFO LTM | 170 |
| CFO 3Y Avg | 182 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.2% |
| Rev Chg 3Y Avg | 1.8% |
| Rev Chg Q | -2.5% |
| QoQ Delta Rev Chg LTM | -0.6% |
| Op Inc Chg LTM | 46.6% |
| Op Inc Chg 3Y Avg | 28.1% |
| Op Mgn LTM | -2.9% |
| Op Mgn 3Y Avg | -7.4% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 11.5% |
| CFO/Rev 3Y Avg | 12.4% |
| FCF/Rev LTM | 5.0% |
| FCF/Rev 3Y Avg | 6.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 1.3 |
| P/Op Inc | -0.3 |
| P/EBIT | -0.3 |
| P/E | -0.3 |
| P/CFO | 5.8 |
| Total Yield | -0.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 4.9% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 42.2% |
| 3M Rtn | 27.2% |
| 6M Rtn | -6.1% |
| 12M Rtn | -32.4% |
| 3Y Rtn | -41.8% |
| 1M Excs Rtn | 29.7% |
| 3M Excs Rtn | 20.5% |
| 6M Excs Rtn | -21.2% |
| 12M Excs Rtn | -54.3% |
| 3Y Excs Rtn | -116.4% |
Price Behavior
| Market Price | $14.82 | |
| Market Cap ($ Bil) | 0.9 | |
| First Trading Date | 06/06/2025 | |
| Distance from 52W High | -44.7% | |
| 50 Days | 200 Days | |
| DMA Price | $18.91 | $18.91 |
| DMA Trend | down | up |
| Distance from DMA | -21.6% | -21.6% |
| 3M | 1YR | |
| Volatility | 56.3% | 65.4% |
| Downside Capture | 0.60 | 1.24 |
| Upside Capture | 205.99 | 120.85 |
| Correlation (SPY) | 28.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.66 | 1.38 | 1.43 | 1.41 | -0.04 | 0.08 |
| Up Beta | 1.27 | 1.18 | 0.80 | 0.73 | 0.33 | -0.66 |
| Down Beta | -8.98 | 0.09 | 0.67 | 0.78 | 0.20 | -0.69 |
| Up Capture | 208% | 231% | 186% | 111% | 97% | 9% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 25 | 34 | 62 | 113 | 113 |
| Down Capture | 485% | 140% | 193% | 202% | 161% | 82% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 17 | 29 | 60 | 108 | 108 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMDA | |
|---|---|---|---|---|
| OMDA | -37.6% | 65.5% | -0.52 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 13.8% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 22.8% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | -2.0% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -7.8% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 8.9% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 15.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMDA | |
|---|---|---|---|---|
| OMDA | -9.0% | 65.5% | -0.52 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 13.8% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 22.8% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | -2.0% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | -7.8% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 8.9% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 15.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMDA | |
|---|---|---|---|---|
| OMDA | -4.6% | 65.5% | -0.52 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 13.8% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 22.8% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | -2.0% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | -7.8% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 8.9% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 15.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | 3.3% | 3.1% | -7.5% |
| 11/6/2025 | -7.1% | -5.0% | -28.4% |
| 8/7/2025 | -2.3% | 4.9% | 23.5% |
| SUMMARY STATS | |||
| # Positive | 1 | 2 | 1 |
| # Negative | 2 | 1 | 2 |
| Median Positive | 3.3% | 4.0% | 23.5% |
| Median Negative | -4.7% | -5.0% | -18.0% |
| Max Positive | 3.3% | 4.9% | 23.5% |
| Max Negative | -7.1% | -5.0% | -28.4% |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 322.00 Mil | 326.00 Mil | 330.00 Mil | 2.8% | Raised | Guidance: 317.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | 14.00 Mil | 17.00 Mil | 20.00 Mil | 54.5% | Raised | Guidance: 11.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 312.00 Mil | 317.00 Mil | 322.00 Mil | 23.4% | Higher New | Actual: 257.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | 7.00 Mil | 11.00 Mil | 15.00 Mil | ||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Shao, Wei-Li | President | Direct | Sell | 4102026 | 12.71 | 2,829 | 35,946 | 4,178,434 | Form |
| 2 | Cook, Steven L | Chief Financial Officer | Direct | Sell | 3172026 | 13.94 | 1,884 | 26,263 | 2,795,137 | Form |
| 3 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 3112026 | 14.34 | 4,063 | 58,276 | 1,686,726 | Form |
| 4 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 1142026 | 15.95 | 40,796 | 650,774 | 2,020,212 | Form |
| 5 | Duffy, Sean P | Chief Executive Officer | Direct | Sell | 1142026 | 15.60 | 230,479 | 3,595,152 | 1,975,470 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.